# EDGAR Filing Document

**Accession Number:** 0001496671
**File Stem:** 0001104659-23-014522
**Filing Date:** 2023-2
**Character Count:** 7176
**Document Hash:** 47f9d0180ba2d440b5c91376c6d31012
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-014522.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001104659-23-014522

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calithera Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001496671
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 272366329
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88349
- **FILM NUMBER:** 23599060

**BUSINESS ADDRESS:**
- **STREET 1:** 343 OYSTER POINT BLVD #200
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-870-1000

**MAIL ADDRESS:**
- **STREET 1:** 343 OYSTER POINT BLVD #200
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **IRS NUMBER:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934<br> (Amendment No. 1)\***

Calithera Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

13089P101

(CUSIP Number)

January 13, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:<br> ¨ Rule 13d-1(b)<br> x Rule 13d-1(c)<br> ¨ Rule 13d-1(d)

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 13089P101 13G (Amendment No. 1) Page 2 of 5 Pages

1. NAMES OF REPORTING PERSONS Incyte Corporation

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br>
(see instructions)<br>
(a) ◻ <br>
(b) ◻

3. SEC USE ONLY<br>

4. CITIZENSHIP OR PLACE OF ORGANIZATION<br>
Delaware

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES <br> BENEFICIALLY <br> OWNED BY <br> EACH <br> REPORTING <br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES <br> BENEFICIALLY <br> OWNED BY <br> EACH <br> REPORTING <br> PERSON WITH | 6. | SHARED VOTING POWER<br>0 |
| NUMBER OF<br> SHARES <br> BENEFICIALLY <br> OWNED BY <br> EACH <br> REPORTING <br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES <br> BENEFICIALLY <br> OWNED BY <br> EACH <br> REPORTING <br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>0 |

---

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>
(see instructions) ◻ <br>

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%

12. TYPE OF REPORTING PERSON (see instructions) CO

CUSIP No. 13089P101 13G (Amendment No. 1) Page 3 of 5 Pages

---

| | |
|:---|:---|
| **Item 1(a)** | Name of Issuer: |
|  | Calithera Biosciences, Inc. |
| **Item 1(b)** | Address of Issuer's Principal Executive Offices: |
|  | 343 Oyster Point Blvd., Suite 200<br> South San Francisco, CA 94080 |
| **Item 2(a)** | Name of Person Filing: |
|  | Incyte Corporation |
| **Item 2(b)** | Address of the Principal Business Office or, if none, Residence: |
|  | 1801 Augustine Cut-Off, Wilmington, DE 19803 |
| **Item 2(c)** | Citizenship: |
|  | Delaware |
| **Item 2(d)** | Title of Class of Securities: |
|  | common stock, par value $0.0001 per share ("Common Stock") |
| **Item 2(e)** | CUSIP Number: |
|  | 13089P101 |
| **Item 3.** | **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:** |
|  | Not applicable |
| **Item 4.** | **Ownership** |

---

(a) Amount beneficially owned: 0 shares

(b) Percent of class: 0%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0 shares

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 0 shares

(iv) Shared power to dispose or to direct the disposition of: 0

CUSIP No. 13089P101 13G (Amendment No. 1) Page 4 of 5 Pages

**Item 5.** **Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable

**Item 8.** **Identification and Classification of Members of the Group.**

Not applicable

**Item 9.** **Notice of Dissolution of Group.**

Not applicable

**Item 10.** **Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

CUSIP No. 13089P101 13G (Amendment No. 1) Page 5 of 5 Pages

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2023

---

| | |
|:---|:---|
| INCYTE CORPORATION | INCYTE CORPORATION |
| By: | /s/ Maria E. Pasquale |
|  | Maria E. Pasquale |
|  | Executive Vice President and |
|  | General Counsel |

---